Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

rsuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manu
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... product choices to a manageable shortlist of bench and floor scales and terminals. ... fit best with the customer’s industry and application. , Side-by-side product comparisons ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... , , , ... a private biotechnology company discovering and developing innovative treatments for ... the department of physiology at the University of California, San ... has joined Solace,s scientific advisory board. , , ...
... , FLAGSTAFF, Ariz., July 24 ... New Zealand, Great Britain, Myanmar, the Philippines and Indonesia are meeting ... Woodlands Hotel to share research findings that will determine the future ... , On Sunday morning, Mayor Sara Presler will welcome ...
... , MADISON, N.J., July 24 Quest Diagnostics Incorporated ... testing, information and services, today announced that the U.S. Food and ... company,s Focus Diagnostics business for its test for detecting the 2009 ... A virus initially referred to as the swine flu virus. ...
Cached Biology Technology:Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control 2FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 2FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 3FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 4FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 5
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Stem cell research promises remedies to many devastating diseases ... disease to paralysis. Totipotent embryonic stem cells have great ... cells that can be used to restore malfunctioning or ... shown that pluripotent stem cells derived from adult bone ...
... as much at home walking four-legged on the ground as ... years ago with the same rare ability, a new study ... the agile walking and climbing skills of the lesser short-tailed ... absence of any ground-dwelling mammal competitors or predators, says an ...
... an enzyme in the brains of newborns suffering from ... brain damage that is a leading cause of cerebral ... Cincinnati Children,s Hospital Medical Center. Reporting their results ... show blocking the brain enzyme, tissue-type plasminogen activator (tPA), ...
Cached Biology News:Stem cell research: From molecular physiology to therapeutic applications 2Stem cell research: From molecular physiology to therapeutic applications 3Stem cell research: From molecular physiology to therapeutic applications 4Bizarre walking bat has ancient heritage 2Experimental treatment halts hypoxic-ischemic brain injury in newborns 2Experimental treatment halts hypoxic-ischemic brain injury in newborns 3
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
... Anti-M13 polyclonal antibody was derived from rabbit ... particles.Recombinant protein domains such as antibody fragments ... pIII and displayed on phage using phagemid-based ... utilized in the Ph.D. libraries. Anti-M13 pIII ...
... T4 Polynucleotide Kinase catalyzes the ... ATP to the 5-terminus of ... a 5-hydroxyl group. The enzyme, ... may be used to phosphorylate ...
... IVF are designed for human in vitro ... setup and operation, and convenience. Chamber, ... displayed on the control panel. Our signature ... by way of the thermal printer inside ...
Biology Products: